Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma

[1]  S. Hofer,et al.  Intravascular large B‑cell lymphoma , 2016, memo - Magazine of European Medical Oncology.

[2]  T. McDonnell,et al.  Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. , 2015, Blood.

[3]  Martin C. Müller,et al.  Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy , 2015, PloS one.

[4]  J. Hasford,et al.  Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death , 2015, Annals of Hematology.

[5]  R. Silver,et al.  Management of chronic myeloid leukemia in blast crisis , 2015, Annals of Hematology.

[6]  K. Spiekermann,et al.  Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV , 2015, Leukemia.

[7]  C. Gambacorti-Passerini,et al.  How I treat newly diagnosed chronic myeloid leukemia in 2015 , 2015, American journal of hematology.

[8]  T. Hocking,et al.  Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis , 2014, Cancer science.

[9]  H. Kantarjian,et al.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia , 2014, Leukemia & lymphoma.

[10]  Francis R. Bach,et al.  SegAnnDB: interactive Web-based genomic segmentation , 2014, Bioinform..

[11]  K. Greulich-Bode,et al.  On the Power of Additional and Complex Chromosomal Aberrations in CML , 2012, Current genomics.

[12]  R. Hehlmann.  How I treat CML blast crisis. , 2012, Blood.

[13]  M. Baccarani,et al.  Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. , 2012, Blood.

[14]  Martin C. Müller,et al.  Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. , 2011, Blood.

[15]  A. Hochhaus.  Educational session: managing chronic myeloid leukemia as a chronic disease. , 2011, Hematology. American Society of Hematology. Education Program.

[16]  S. Kimura,et al.  Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma , 2011, Annals of Hematology.

[17]  M. Baccarani,et al.  Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. , 2010, Cancer genetics and cytogenetics.

[18]  Miguel Vicente-Manzanares,et al.  Non-muscle myosin II takes centre stage in cell adhesion and migration , 2009, Nature Reviews Molecular Cell Biology.

[19]  T. Naoe,et al.  Presentation and management of intravascular large B-cell lymphoma. , 2009, The Lancet. Oncology.

[20]  F. Cavalli,et al.  The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma , 2008, British journal of haematology.

[21]  T. Naoe,et al.  Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Djokic.  Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5 , 2008 .

[23]  S. Kimura,et al.  Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. , 2007, Mayo Clinic proceedings.

[24]  E. Campo,et al.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Naoe,et al.  Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy , 2007, International journal of hematology.

[26]  Peter J Houghton,et al.  Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.

[27]  T. Naoe,et al.  Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice , 2007, Leukemia.

[28]  J. Radich.  The Biology of CML blast crisis. , 2007, Hematology. American Society of Hematology. Education Program.

[29]  M. Okigaki,et al.  Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab. , 2006, Clinical nephrology.

[30]  Mamoru Ito,et al.  Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. , 2005, Cancer Science.

[31]  T. Hara,et al.  Lymph Node Fibroblastic Reticular Cells Construct the Stromal Reticulum via Contact with Lymphocytes , 2004, The Journal of experimental medicine.

[32]  H. Tagawa,et al.  Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma , 2004, Cancer Research.

[33]  A. López-Guillermo,et al.  Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[35]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[36]  S. Gill,et al.  Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. , 2003, The American journal of medicine.

[37]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[38]  B. Johansson,et al.  Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia , 2002, Acta Haematologica.

[39]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[40]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Suchi,et al.  An Asian variant of intravascular large B‐cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B‐cell lymphoma associated with haemophagocytic syndrome , 2000, British journal of haematology.

[42]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[43]  G. Arrigoni,et al.  Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. , 2000, Human pathology.

[44]  S. Narumiya,et al.  Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. , 1999, Science.

[45]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.